A Phase I Trial of the IGF‐1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer

PURPOSE. This study evaluated the maximum tolerated dose or recommended phase II dose (RPTD) and safety and tolerability of the ganitumab and everolimus doublet regimen followed by the ganitumab, everolimus, and panitumumab triplet regimen. MATERIALS AND METHODS. This was a standard 3 + 3 dose escal...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Oncologist
المؤلفون الرئيسيون: Vlahovic, Gordana, Meadows, Kellen L., Hatch, Ace J., Jia, Jingquan, Nixon, Andrew B., Uronis, Hope E., Morse, Michael A., Selim, M. Angelica, Crawford, Jeffrey, Riedel, Richard F., Zafar, S. Yousuf, Howard, Leigh A., O'Neill, Margot, Meadows, Jennifer J., Haley, Sherri T., Arrowood, Christy C., Rushing, Christel, Pang, Herbert, Hurwitz, Herbert I.
التنسيق: Artigo
اللغة:Inglês
منشور في: AlphaMed Press 2018
الموضوعات:
Gastrointestinal Cancer
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC6058343/
https://ncbi.nlm.nih.gov/pubmed/29572245
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0377
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة